VCEL vs MGTX vs RCKT vs FATE vs AGIO

For growth investors, MeiraGTx Holdings plc (MGTX) is the stronger pick with 137.

4% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). Vericel Corporation (VCEL) offers the better valuation at 114. 9x trailing P/E (84. 6x forward), making it the more compelling value choice. Analysts rate Vericel Corporation (VCEL) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, MeiraGTx Holdings plc (MGTX) delivered a total return of -26.

4%, compared to -97. 0% for Fate Therapeutics, Inc. (FATE). Over 10 years, the gap is even starker: VCEL returned +1283% versus RCKT's -90. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Agios Pharmaceuticals, Inc.

(AGIO) is the lower-risk stock at 1. 12β versus Fate Therapeutics, Inc. 's 2. 17β — meaning FATE is approximately 95% more volatile than AGIO relative to the S&P 500. On balance sheet safety, Agios Pharmaceuticals, Inc. (AGIO) carries a lower debt/equity ratio of 5% versus 125% for MeiraGTx Holdings plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), MeiraGTx Holdings plc (MGTX) is pulling ahead at 137.

4% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: Vericel Corporation grew EPS 60. 0% year-over-year, compared to -161. 2% for Agios Pharmaceuticals, Inc.. Over a 3-year CAGR, AGIO leads at 56. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Vericel Corporation (VCEL) is the more profitable company, earning 6.

0% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 6. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VCEL leads at 4. 0% versus -22. 2% for FATE. At the gross margin level — before operating expenses — AGIO leads at 78. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for FATE: 1624.

9% to $39. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Vericel Corporation (VCEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+1283% 10Y return).

Fate Therapeutics, Inc. (FATE) carries a higher beta of 2. 17 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VCEL: +1283%, FATE: +33. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VCEL is a small-cap high-growth stock; MGTX is a small-cap high-growth stock; RCKT is a small-cap quality compounder stock; FATE is a small-cap quality compounder stock; AGIO is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.